Amarin Corp Plc (AMRN)

[ziploc_1]

Card...in the AZN vs. Apotex case...QUOTE from the court..."the court held that a manufacturer that intends to place a drug on the market knowing it will be used in an infringing manner by some consumers would be liable for inducing infringement, for which the appropriate remedy is an injunction. The court said it did not matter that the
infringing use was mandated by FDA requirements, because
the manufacturer had other options for avoiding inducement."

I believe this definitely applies to Amarin's Vascepa being used by Generics for the R-IT indications.